Alexander Heyliger

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19

Raymund R. Razonable, Nicole C.E. Aloia, Ryan J. Anderson et al. · Mayo Clinic Proceedings · 2021 · 54 citations · Full text

Pharmacy, Health Informatics, Infectious Diseases +17

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Ravindra Ganesh, Colin Pawlowski, John C. O’Horo et al. · Journal of Clinical Investigation · 2021 · 46 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +7

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

Raymund R. Razonable, John C. O’Horo, Sara N. Hanson et al. · The Journal of Infectious Diseases · 2022 · 37 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Potential cost savings associated with dose rounding antineoplastic monoclonal agents

Sarah M. Francis, Alexander Heyliger, Marta A. Miyares et al. · Journal of Oncology Pharmacy Practice · 2014 · 28 citations

Pharmacy, Oncology, Pharmacoeconomics +14

A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID‐19 in skilled care facilities

Sidna M. Tulledge‐Scheitel, Sarah Bell, Jennifer J. Larsen et al. · Journal of the American Geriatrics Society · 2021 · 27 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16